GlaxoSmithKline Pharmaceuticals Ltd Posts Strong Q4 Profits

GlaxoSmithKline Pharmaceuticals Ltd reported a 5.7% increase in net profit for Q4, reaching Rs 277.86 crore. The company's revenue rose to Rs 995.3 crore. For FY26, net profit was Rs 1,035.98 crore. A final dividend of Rs 57 per share is proposed, pending shareholder approval.

GlaxoSmithKline Pharmaceuticals Ltd showcased its financial resilience with a 5.7% rise in consolidated net profit for the fourth quarter, ending at Rs 277.86 crore, compared to the previous year's Rs 262.87 crore.

The company's consolidated revenue from operations for the quarter also saw an uptick, rising to Rs 995.3 crore from the last year's Rs 974.37 crore, as the company reported in a regulatory filing.

For the full fiscal year 2026, GlaxoSmithKline recorded a consolidated net profit of Rs 1,035.98 crore, marking growth over FY25's Rs 927.58 crore, while annual revenue increased to Rs 3,821.67 crore. A dividend proposal of Rs 57 per equity share awaits shareholder approval.